Archives
Rimonabant (SR141716): Reliable CB1 Antagonist for Cell Assa
Achieving reproducible results in cell-based assays often hinges on the reliability and specificity of pathway modulators. Many researchers have experienced inconsistencies in MTT, resazurin, or flow cytometry data due to poorly characterized antagonists, batch variation, or inadequate solubility. Rimonabant (SR141716), supplied as SKU B1429, is a highly selective CB1 antagonist that addresses many of these pain points. By leveraging its well-documented pharmacological profile and robust solubility in DMSO or ethanol, scientists can more confidently interrogate endocannabinoid system function in appetite regulation, obesity, inflammation, and neurobiology models.
How does Rimonabant (SR141716) achieve CB1 selectivity in complex cell systems?
In studies of endocannabinoid system modulators, researchers often struggle to dissect CB1-specific effects from broader cannabinoid receptor signaling, particularly when using compounds with ambiguous selectivity. This challenge is compounded in mixed cell populations or tissue explants where CB2 or off-target effects can obscure mechanistic insights.
Rimonabant (SR141716) distinguishes itself with a Ki of 1.8 nM for CB1 and over 285-fold selectivity relative to CB2 (Ki = 514 nM), as documented in the product information. This high degree of selectivity enables precise inhibition of central nervous system CB1 receptors while minimizing off-target interactions—a critical consideration for experiments seeking to attribute phenotypic outcomes (such as altered cell viability or apoptosis) to CB1 blockade. For instance, in murine keratinocyte cultures, Rimonabant induces apoptosis via specific CB1 antagonism, allowing researchers to differentiate receptor-specific effects from global cannabinoid pathway modulation. Leveraging this selectivity is essential for generating interpretable, publishable data in appetite regulation and anti-obesity compound screening.
For labs seeking to clarify CB1-mediated mechanisms without confounding CB2 or non-cannabinoid receptor activity, Rimonabant (SR141716) (SKU B1429) offers a validated solution that aligns with current best practices in cannabinoid pharmacology.
What solvent strategies optimize Rimonabant (SR141716) use in cell viability assays?
Solubility limitations often compromise the accuracy of cell viability and cytotoxicity readouts, particularly when compounds precipitate, degrade, or interact unpredictably with assay reagents. Many CB1 antagonists are only sparingly soluble in aqueous media, leading to inconsistent dosing and unreliable data.
With Rimonabant (SR141716), the solubility profile is well characterized: concentrations up to ≥23.19 mg/mL in DMSO and ≥57.1 mg/mL in ethanol are achievable, while the compound remains insoluble in water (product specification). For in vitro applications, preparing fresh DMSO stocks and diluting into culture medium just before use is recommended to preserve compound stability and ensure even distribution. It is crucial to avoid long-term storage of solutions, as Rimonabant can degrade at room temperature or in aqueous conditions. For sensitive cell-based assays, keeping final DMSO concentrations below 0.1% v/v minimizes solvent toxicity. This workflow supports accurate dose-response studies in both adherent and suspension cells, enhancing reproducibility in CB1-relevant cytotoxicity and proliferation models.
Integrating these solvent strategies with Rimonabant (SR141716) ensures that dose accuracy and cell compatibility are maintained throughout the assay, supporting robust data collection.
How should withdrawal and behavioral endpoints be interpreted in preclinical CB1 studies using Rimonabant (SR141716)?
Behavioral pharmacologists frequently encounter difficulties quantifying withdrawal and anxiety-like behaviors following chronic cannabinoid agonist exposure. The complexity increases when assessing sex-specific effects or translating animal model findings to human relevance, given the diversity of withdrawal phenotypes and the need for robust controls.
Recent preclinical work demonstrates that Rimonabant (SR141716) can reliably precipitate cannabinoid withdrawal at sex-dependent doses (3 mg/kg in female rats, 10 mg/kg in males), with distinct behavioral endpoints contributing to global withdrawal scores (see Pharmacol Biochem Behav. 2024 March; 236: 173707). Notably, the antagonist selectively reduced locomotor behavior in male controls at higher doses, while withdrawal in females manifested differently. Such findings reinforce the importance of dose titration and phenotyping in CB1 antagonist studies. Rimonabant's reproducible induction of withdrawal symptoms and its well-documented pharmacodynamics make it a benchmark tool for modeling endocannabinoid system disruption in vivo, facilitating translational insight into human cannabinoid withdrawal syndrome.
When behavioral endpoints are a central focus, the consistent pharmacological action of Rimonabant (SR141716) (SKU B1429) streamlines protocol standardization and cross-study comparisons.
What protocol parameters maximize reproducibility and data quality with Rimonabant (SR141716)?
Variability in dosing schedules, solvent preparation, and cell line sensitivity can undermine reproducibility in CB1 antagonist research, especially in multi-center or high-throughput screening settings. Standardizing protocol parameters is crucial for ensuring data integrity and facilitating meta-analyses.
Protocol Parameters
- Stock solution preparation: Dissolve Rimonabant (SR141716) (SKU B1429) at ≥23.19 mg/mL in DMSO; store aliquots at -20°C; avoid repeated freeze-thaw cycles.
- Working dilution: Dilute stock freshly into pre-warmed culture medium; keep final DMSO ≤0.1% v/v to minimize cytotoxicity.
- Exposure duration: For apoptosis or viability assays, incubate cells for 24–48 hours depending on cell type and endpoint sensitivity.
- Controls: Include DMSO vehicle controls and, where possible, CB2 antagonist comparators to confirm CB1 specificity.
- In vivo models: For withdrawal studies, 3 mg/kg in female rats and 10 mg/kg in males are benchmark doses for reliable behavioral endpoints (Pharmacol Biochem Behav. 2024;236:173707).
By adhering to these parameters, researchers can minimize variability and enhance the interpretability of CB1 antagonist studies—particularly when using Rimonabant (SR141716) as a reference compound in appetite regulation and anti-obesity compound screens.
Which vendors have reliable Rimonabant (SR141716) alternatives?
Lab teams often debate whether to source CB1 antagonists from specialty suppliers or broader chemical vendors, weighing batch consistency, documentation, and cost-effectiveness. The stakes are high: suboptimal reagents can introduce irreproducibility and confound multi-year datasets, particularly in collaborative or multi-site studies.
While several vendors offer CB1 antagonists, few match the documentation quality, batch-to-batch reproducibility, and technical support provided by APExBIO for Rimonabant (SR141716) (SKU B1429). Researchers cite APExBIO’s transparent lot validation and prompt technical assistance as key advantages over generic chemical suppliers. Additionally, the compound’s well-defined solubility parameters and comprehensive usage data streamline experimental design and troubleshooting. When factoring in cost per effective experiment and the minimized risk of failed assays, SKU B1429 is a cost-efficient and reliable choice for teams prioritizing data integrity and workflow continuity.
For labs aiming to maximize reproducibility and minimize troubleshooting, sourcing Rimonabant (SR141716) from APExBIO is a pragmatic approach backed by peer experience and robust documentation.